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Abstract
The high prevalence and costs of type 2 diabetes makes it a rapidly evolving focus of policy 
action. Health systems, employers, community organizations, and public agencies have 
increasingly looked to translate the benefits of promising research interventions into innovative 
polices intended to prevent or control diabetes. Though guided by research, these health policies 
provide no guarantee of effectiveness and may have opportunity costs or unintended 
consequences. Natural experiments use pragmatic and available data sources to compare specific 
policies to other policy alternatives or predictions of what would likely have happened in the 
absence of any intervention. The Natural Experiments for Translation in Diabetes (NEXT-D) 
Study is a network of academic, community, industry, and policy partners, collaborating to 
advance the methods and practice of natural experimental research, with a shared aim of 
identifying and prioritizing the best policies to prevent and control diabetes. This manuscript 
describes the NEXT-D Study group's multi-sector natural experiments in areas of diabetes 
prevention or control as case examples to illustrate the selection, design, analysis, and challenges 
inherent to natural experimental study approaches to inform development or evaluation of health 
policies.
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About 29 million Americans have diabetes, and another 86 million have prediabetes, placing 
them at high risk for progression to type 2 diabetes as well as additional health problems, 
lower quality of life, and higher medical and non-medical costs.1 Recent increases in the 
burden of type 2 diabetes have encouraged rapid policy action by both public agencies and 
private organizations. Optimistically, many agencies and organizations have attempted to 
implement interventions derived from seminal research studies, often making adaptations to 
enhance access, feasibility, and scalability. For example, recent policy action established a 
national recognition program at CDC to define standards for how community organizations 
should offer lifestyle-based diabetes prevention programs consistent with the Diabetes 
Prevention Program (DPP) clinical trial.2 Similarly, value-based health insurance designs are 
being implemented by some health systems to reduce or eliminate out-of-pocket costs for 
preventive services or medications that have strong evidence of benefit.3
Although the use of past research to inform diabetes-related health policies is encouraging, 
there is no guarantee that an intervention derived from a successful clinical trial will be 
effective or cost effective under real-life circumstances. For example, clinical trials have 
demonstrated that intensive interventions to support diabetes self-management improve 
glycemic control and cardiovascular risk factors,4,5 but policies by health payers to fund 
disease management interventions in diabetes and many other areas have yielded mixed 
results.6,7 Similarly, duplicative prescribing and poly-pharmacy can increase adverse 
medication events, but policies that cap the number of medications covered by state-based 
public assistance programs have been linked to lower use of recommended glucose-lowering 
agents, increased hospitalization, and higher public expenditures.8,9 Unintended policy 
consequences, such as the potential to exacerbate rather than reduce health disparities, are 
also an important target for health policy research.10,11 Ideally, when a health policy is 
enacted, ongoing strong research would establish whether the benefits outweigh harms, and 
if costs are reasonable for society.12 Unfortunately, many health policies still remain 
unevaluated or are assessed using research designs that are vulnerable to considerable bias 
and are thus potentially misleading.13
Selecting Valid Research Designs for a Policy Intervention
Although randomized trials are the gold standard for clinical efficacy research, they are often 
impractical or inappropriate to test policy effectiveness.14,15 Conversely, natural experiments 
use pragmatic research designs and readily available data sources to evaluate and compare a 
new or existing policy to other policy alternatives or predictions of what may have happened 
in the absence of any intervention.14,16,17 Natural experiments have been applied to 
numerous disciplines, including political science, education, psychology, economics, history, 
and sociology.17–19 Within the context of health research, natural experiments have been 
particularly influential in policies related to indoor tobacco laws, Medicaid drug 
reimbursement policies, and provision of vouchers for health and social services.20–24
For each policy intervention, there is typically more than one choice for a natural 
experimental study design, with the goal of implementing the strongest design feasible given 
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the study question, implementation context, and data sources available. Table 1 provides 
examples of several common design options, including how adequately they address 
common threats to validity.
Individually randomized trials are often difficult to implement but should still be considered 
in the evaluation of public or organizational policies.24,25 When individual randomization is 
not feasible, adaptations to the RCT design, such as cluster-randomized parallel-group or 
stepped-wedge intervention trials can provide strong alternatives by allocating groups to 
interventions at a provider, clinical practice, organizational, community, or regional 
level.26,27 Importantly, such designs must carefully consider decreases in the effective 
sample size, the possibility of imbalance among treatment groups when randomized clusters 
are small, and the need for special statistical models to account for correlation of outcomes 
within clusters.27
If no form of randomization is feasible or appropriate, the interrupted time series design 
(with and without control series), and to a lesser extent, pre–post studies with a strongly 
matched comparison group provide alternatives that can control for most common threats to 
validity.17 These designs must carefully consider common threats such as bias and 
confounding and the role of complementary statistical approaches to address these threats 
during the analysis. Examples of such approaches include multivariable adjustment or 
propensity matching with or without adjustment. Another important strategy to reduce 
uncertainty for a particular study design is to replicate findings by repeating the analysis in 
another context (i.e., external validation) or through sensitivity analyses that examine 
whether similar results are achieved using alternative comparison groups or study design 
options. Although used in many past policy evaluations, simple cross-sectional or pre–post 
designs without a comparison group are generally considered weak for evaluating 
intervention effectiveness. As reflected in Table 1, these designs are attractive because of 
their simplicity but can be misleading, as they are unable to control for common biases such 
as history and selection.
The Natural Experiments for Translation in Diabetes Study
The Natural Experiments for Translation in Diabetes (NEXT-D) study is a dynamic 
collaboration among five academic centers, numerous organizational and policy partners, 
CDC, and the National Institute of Digestive and Diabetes and Kidney Diseases. NEXT-D 
centers include the Harvard Pilgrim Health Care Institute and Harvard Medical School, 
Kaiser Permanente Northern California, Northwestern University, New York St. Luke's-
Roosevelt Hospital, and the University of California, Los Angeles (UCLA). Each of these 
centers has an evaluation partnership with one or more non-academic entities to evaluate a 
public or organizational policy area using a natural experimental study design that is 
practical, methodologically rigorous, and suited to the needs and interests of each policy 
stakeholder. By including policy decision makers in the network, NEXT-D seeks to address 
the most relevant gaps in the scientific research literature while developing data collection, 
analysis, interpretation, and communication strategies to improve policy decision making. 
Partnering directly with policy stakeholders also increases the likelihood that research 
findings will be translated into real-life policies and practice.28
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The NEXT-D study group adopted a conceptual framework to portray the relationships 
among NEXT-D projects. This framework was derived from existing social-ecologic 
heuristics29,30 and considers how each natural experiment might be affected by other 
interventions or contextual influences across geographic, organizational, and economic 
sectors. Using the framework, the study group considers how best to design natural 
experiments to evaluate how policies are adopted and implemented, whom they reach, and 
whether they are effective and sustainable. The goal for each natural experiment is a 
rigorously designed quasi-experimental study that carefully considers the individual and 
synergistic effects of influences at multiple policy levels.15,16 These interactive effects are 
depicted in Figure 1 and explored briefly in the text that follows.
A central focus of the framework is to understand the intended or unintended impacts of 
policies enacted at any level. These impacts can be related to diabetes incidence, 
progression, or health and economic outcomes, as well as the distribution of those outcomes 
(e.g., reducing or increasing health disparities) throughout the population. Policies impact 
these key outcomes either directly or indirectly through effects that ultimately must 
culminate in successful changes in the behaviors of individuals or others such as healthcare 
providers, public health professionals, community health workers, or peers.
The health system is portrayed as the smallest sphere, underscoring its modest yet important 
influence on overall population health outcomes relative to other sectors, primarily via 
behavioral, preventive, and health-care services. Examples include clinical practice 
recommendations, public reporting of quality metrics, new resources for health promotion 
and self-management support, and the implementation of electronic health record systems to 
coordinate healthcare and behavioral support services.31,32 At a slightly broader level, the 
sponsors or purchasers of healthcare services, such as public agencies (e.g., Centers for 
Medicare and Medicaid Services [CMS], state Medicaid offices) and employers, are 
depicted as investing in efforts (implemented either directly or via health plan partners) to 
improve patient and provider behaviors, and to offer additional resources and services to 
support those behaviors. Examples include the design of new coverage benefits, special 
programs to support prevention and care management, and restructuring payments to 
incentivize behaviors that lead to better health and health care.33–36
Individuals and populations also regularly interact with community resources from religious, 
civic, socially driven, or commercial entities. Community resources are a crucial influence 
on health-related behaviors and health status. For example, faith-based organizations play an 
increasing role in social support, self-management, and even clinical services for people 
with diabetes or prediabetes.37
Finally, the public policy environment may play a strong role in influencing health through 
actions such as the development of laws and regulations to shape the economic, physical, 
social, and cultural environments in which people live, work, and recreate. Public policies 
may result in both intended and unintended consequences through direct regulatory impacts 
or via interactions with other interventions that are deployed simultaneously across other 
levels.
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Examples of Existing Natural Experiments Supported by NEXT-D
Diverse study designs are employed in NEXT-D to determine the impacts of policies enacted 
at multiple levels. Below, we describe very briefly the existing NEXT-D projects as case 
examples for the selection, design, analysis, and challenges of using robust natural 
experimental research designs to inform the evolution of policies in public health and 
healthcare contexts.
Example 1: Kaiser Permanente Northern California
Telephonic coaching to encourage healthy lifestyle choices is a population-based approach 
to wellness and diabetes prevention that is being explored by many health plans and 
purchasers. As gestational diabetes mellitus (GDM) has increased in incidence, more health 
plans are also implementing strategies to encourage glucose screening for earlier 
identification and treatment of both type 2 diabetes and prediabetes postpartum. Kaiser 
Permanente Northern California (KPNC) has partnered with a large healthcare purchaser to 
assess the impact of providing population-based telephonic wellness coaching, as well as a 
postpartum diabetes risk-reduction intervention targeting women who have had GDM.38 
These studies use multiple data sources and interrupted time series with control series, as 
well as pre–post longitudinal control group designs to assess patient satisfaction, perceptions 
of the programs, BMI, smoking-cessation rates, hemoglobin A1c and fasting plasma glucose 
levels, and onset of diabetes in populations. The studies will also examine potential impacts 
on health care and health disparities, as well as the efficiency and programmatic costs to 
help stakeholders understand the barriers and facilitators to expanding these programs within 
the health plan if they are found to be effective.
Example #2: University of California, Los Angeles
At UCLA, investigators are partnering with the Innovations Group at United Healthcare, the 
largest commercial health insurance company in the U.S., to evaluate the health and 
economic impacts of a new diabetes-specific health insurance benefits package. The 
Diabetes Health Plan (DHP), which is now being offered by several dozen large- and 
medium-sized employers throughout the U.S., providing chronic condition management, 
financial incentives, and improved access to value-based services (e.g., established 
preventive medications, treatments, and services at very low or no cost) for patients with 
prediabetes and diabetes.39 The study uses a longitudinal quasi-experimental design with a 
propensity-matched comparison group of employers who do not offer the DHP to evaluate 
the effect on adherence to evidence-based medications, use of emergency department or 
hospital inpatient services, rates of progression from prediabetes to diabetes, and total costs 
of care. UCLA meets regularly with United's Innovations Group to ensure that the study's 
findings will help United make decisions about further DHP refinements and its replication. 
This study also will determine what employers should expect when implementing this type 
of disease-specific plan in real-world settings, where program uptake and employee 
engagement can vary.
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Example #3: St. Luke's-Roosevelt Health System
Investigators at St. Luke's-Roosevelt are collaborating with six primary care clinics in New 
York City to study pragmatic interventions at the health system/provider level that address 
challenges to early diabetes detection and prevention in primary care practice. Interventions 
use chronic care model principles and involve electronic health record modifications and 
integrated health care systems/community linkages that are rolled out across each clinic in a 
stepped fashion, allowing for comparisons over time as well as across implementing and 
non-implementing clinics. Using electronic health record data sources and a time series 
study design, this study will compare rates of test completion and detection of diabetes or 
prediabetes. A pre–post with propensity-matched comparison group study design will be 
used to determine the effects of the enhanced management interventions on clinical 
intermediate outcomes (e.g., hemoglobin A1c), for about 1,500 adults who are identified as 
having prediabetes or type 2 diabetes who receive care at a practice location implementing 
(versus not implementing) the enhanced interventions.40 Evaluation results will inform the 
continuing implementation and wider replication of enhanced management intervention 
strategies to other clinics in the network.
Example #4: Harvard Pilgrim Health Care Institute
More than 40% of workers now have high-deductible health plans (HDHPs),41 and recent 
policies are expected to spur further increases because of coverage mandates, incentives for 
plans with lower actuarial value (non-“Cadillac” plans), and greater upfront affordability.42 
It is not yet known whether HDHPs will have their intended effect of creating “activated 
healthcare consumers” who change their behaviors and seek higher-value services to lower 
their own health expenditures or, rather, who simply reduce utilization, even for care that is 
considered essential. Harvard partnered with OptumInsight Life Sciences, Inc., to develop a 
national data set involving a 13-year rolling sample (2001–2013) of 1.3 million adults with 
diabetes from all 50 states who are health plan members of an HDHP or more traditional 
plans (controls). The study is employing an interrupted time series with comparison series 
study design to assess the impact of HDHPs on diabetes control, risk factors, preventive 
care, and health outcomes such as emergency department visits and preventable 
hospitalizations; utilization, including outpatient visits; and costs.43–45 Results of this work 
could be used to design health plan features that promote more equitable high-quality care 
and better outcomes among patients with diabetes.
Example #5: Northwestern University Feinberg School of Medicine
To address the growing incidence of type 2 diabetes in the U.S., UnitedHealth Group 
(UHG), Y-USA, and CDC have partnered to bring a group-based adaptation of the DPP 
lifestyle intervention to a national scale. This initiative combines actions at the purchaser, 
community resource, and public policy levels and leverages efforts by CDC and Y-USA to 
build the capacity of community organizations nationwide to deliver a standardized lifestyle 
intervention program derived from the DPP.46 These interventions ultimately target several 
million eligible adults with prediabetes in almost 50 large geographic markets throughout 
the U.S. The study will use an interrupted time series with propensity-matched comparison 
series design to determine the relative effects of UHG outreach/engagement activities and 
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local efforts by YMCAs to enroll participants within different demographic subgroups. By 
integrating additional data from Y-USA, the project will examine how implementation varies 
across regions, and using national UHG claims data sources, effectiveness will be evaluated 
through changes in prescription expenditures; obesity-related risk factors such as total 
cholesterol and blood glucose; healthcare utilization; and total healthcare expenditures.46
Discussion
New public and organizational policies are being enacted every day to improve health and 
behavior, but we continually miss important opportunities to evaluate those policies using 
valid research designs. Natural experiments are forms of pragmatic research that use readily 
available data sources to evaluate and compare the intended and unintended outcomes of 
new or existing policies, rather than simply assume they are a wise use of limited resources. 
No study design is without limitation; thus, the process of selecting a natural experimental 
approach must carefully consider the trade-offs between feasibility and scientific validity.
Ideally, the design of a natural experiment should be deliberated within the context of a 
partnership that includes capable evaluators, policy decision-makers, and other stakeholders. 
Together, these partners must consider important choices and ultimately select a design that 
will be feasible to implement while providing organizational leaders and other individuals 
with valid and actionable outcomes, such as who can be reached by new initiatives; whether 
all target groups have equitable access; if benefits vary across different vulnerable 
population subgroups; if there are unintended consequences; and the amount and types of 
expenditures that are needed to implement those initiatives “at scale.” Such research can be 
considered one badly needed form of implementation science, which seeks to elucidate how 
best to replicate and scale evidence-based programs across diverse populations and differing 
settings. Partners may also collaborate to devise creative strategies for overcoming common 
pragmatic research challenges, such as the paucity of information available in administrative 
data systems to determine the characteristics of target populations (e.g., race/ethnicity or 
SES). Overcoming these challenges might require linkages with other data sources, such as 
neighborhood-level data regarding socioeconomic indicators, or the use of individual 
surname analysis done prior to de-identifying the data for analysis. These are but a few of 
the examples of the common challenges that can be solved collaboratively through research 
partnerships, or even networks of partnerships, as is the case in NEXT-D.
With an eye on quantifying the intended and unintended impacts of population-targeted 
diabetes prevention and control initiatives, the NEXT-D network is positioned to provide 
empirical and pragmatic information to guide the ongoing evolution of policies and practices 
to improve diabetes care and prevention. Through the expanded use of strong natural 
experimental methods, NEXT-D evaluates public health and health-care policies while those 
policies are being implemented “unperturbed,” in a fashion that truly reflects health impacts 
for real-world populations and at natural levels of “exposure” (or “dosage”). Although the 
individual natural experimental methods adopted by NEXT-D sites are not entirely novel, the 
support of a network of collaborating academic, health system, public health, commercial, 
and community stakeholders to advance the evolution of health policies in chronic disease 
care and prevention is quite unique. In addition, although NEXT-D focuses on diabetes, its 
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collaborative approach for conceptualizing the policy environment, engaging policy partners 
in the design and application of natural experiments, and transferring findings back to key 
stake-holders in ways that promote continual progress toward more efficient and effective 
population health initiatives is not only relevant but of paramount importance to the entire 
policy community.
Acknowledgments
The Natural Experiments for Translation in Diabetes (NEXT-D) Study is funded jointly by CDC and the NIH/ 
National Institute of Diabetes and Digestive and Kidney Diseases under grant numbers U58-DP002717, DP002718, 
DP002719, DP002721, and DP002722. The findings and conclusions in this report are those of the authors and do 
not necessarily represent the views of CDC or the NIH.
The NEXT-D Study Group: Harvard Medical School and Harvard Pilgrim Healthcare Institute: Frank Wharam, 
MB, BCh, BAO MPH (Co–Principal Investigator [PI]), Steve Soumerai, ScD, MSPH, Connie Trinacty, PhD, Emma 
Eggleston, MD, MPH, Fang Zhang, PhD, Christine Lu, PhD, Robert LeCates, MA, Claire Canning, MA, Dennis 
Ross-Degnan, ScD, MSPH (Co-PI); Kaiser Permanente Northern California: Julie A. Schmittdiel, PhD (PI), 
Assiamira Ferrara, MD, PhD, Romain S. Neugebauer, PhD, Sara Adams; Northwestern University: Ronald T. 
Ackermann, MD, MPH (PI), Joyce Tang, MD, Dustin D. French, PhD, Andrew Cooper, MS, Raymond Kang, MS, 
David T. Liss, PhD, Margaret Moran, MPH, and Indiana University: Chandan K. Saha, PhD, Ann M. Holmes, PhD; 
St. Luke's-Roosevelt: Jeanine B. Albu, MD (PI), Nancy Sohler, PhD, Brenda Matti, MD, Edwin Young, MD, Gary 
Burke, MD, F.X. Pi-Sunyer, MD, Nicholas Freudenberg, PhD, Jordan Sill, MS, Dan Baxter, MD; University of 
California, Los Angeles: Carol M. Mangione, MD, MSPH (Co-PI), O. Kenrik Duru, MD, MS (Co-PI), Susan 
Ettner, PhD, Lindsay Kimbro, MPP, Norman Turk, MS, Jinnan Li, MPH, Ekatarina Vaisberg, Neil Steers, PhD; 
CDC Division of Diabetes Translation: Edward W. Gregg, PhD, Mohammed K. Ali, MBChB, MSc, MBA (also 
Emory University), Bernice Moore, MBA, Meda E. Pavkov, MD, Rui Li, PhD, Theodore Thompson, MS, Ping 
Zhang, PhD; National Institute of Diabetes and Digestive and Kidney Diseases: Sanford A. Garfield, PhD, Christine 
Hunter, PhD.
The NEXT-D Study Group would also like to acknowledge the support of our partners and collaborators, including 
UnitedHealthcare (Anya Kirvan, RN, MS, Bob Luchs, MS, MPHL, Abigail Keckhafer, MBA, MPH, Charles Chan, 
CMA, MS); Y-USA (Matt M. Longjohn, MD MPH, Rachel L Karabenick, Heather Hodge, Katherine H. Hohman); 
United-Health Center for Health Reform and Modernization (Deneen Vojta, MD, Tom Beauregard); the Diabetes 
Prevention and Control Alliance at UnitedHealth Group (Joel French, Satish Bandapati); OptumInsight Life 
Sciences, Inc.; additional partners at Kaiser Permanente Northern California (Vicki George, Andi Fargeix, Nancy 
Goler MD, Rashel Sanna, Mindy Boccio, David J. Bellamy); and healthcare providers and executive leadership 
affiliated with St. Luke's-Roosevelt and partnering delivery systems (particularly Sylvaine Frances, PA, CDE, Eva 
Johansson RN, VP, SLRHC, City University of New York students, the William F. Ryan Community Health Center 
[Barbara Hood and Dustin Prybzilla], Alex Botta, PhD, Julian Botta, BS, and Fera Ps Inc.).
References
1. CDC.. National diabetes statistical report: estimates of diabetes and its burden in the United States, 
2014. DHHS; CDC; Atlanta, GA: 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-
diabetes-report-web.pdf
2. CDC.. National Diabetes Prevention Program. CDC; Atlanta, GA: 2012. www.cdc.gov/diabetes/
prevention/index.htm
3. Fendrick AM. Value-based insurance design for diabetes mellitus: approaches to optimal 
pharmacoeconomic implementation. Am J Manag Care. 2010; 16((11) (suppl)):S314–S322. 
[PubMed: 21517647] 
4. Deakin T, McShane CE, Cade JE, Williams RD. Group based training for self-management 
strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; 
(2):CD003417. [PubMed: 15846663] 
5. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with 
type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002; 25(7):1159–
1171. http://dx.doi.org/10.2337/diacare.25.7.1159. [PubMed: 12087014] 
Ackermann et al. Page 8













6. Chodosh J, Morton SC, Mojica W, et al. Meta-analysis: chronic disease self-management programs 
for older adults. Ann Intern Med. 2005; 143(6):427–438. http://dx.doi.org/
10.7326/0003-4819-143-6-200509200-00007. [PubMed: 16172441] 
7. Peikes D, Chen A, Schore J, Brown R. Effects of care coordination on hospitalization, quality of 
care, and health care expenditures among Medicare beneficiaries: 15 randomized trials. JAMA. 
2009; 301(6):603–618. http://dx.doi.org/10.1001/jama.2009.126. [PubMed: 19211468] 
8. Bishop CE, Ryan AM, Gilden DM, Kubisiak J, Thomas CP. Effect of an expenditure cap on low-
income seniors’ drug use and spending in a state pharmacy assistance program. Health Serv Res. 
2009; 44(3):1010–1028. http://dx.doi.org/10.1111/j.1475-6773.2009.00951.x. [PubMed: 19291168] 
9. Soumerai S. Unintended outcomes of medicaid drug cost-containment policies on the chronically 
mentally ill. J Clin Psychiatry. 2003; 64(suppl 17):19–22.
10. Woolf SH, Braveman P. Where health disparities begin: the role of social and economic 
determinants—and why current policies may make matters worse. Health Aff (Millwood). 2011; 
30(10):1852–1859. http://dx.doi.org/10.1377/hlthaff.2011.0685. [PubMed: 21976326] 
11. McHugh MD, Carthon JM, Kang XL. Medicare readmissions policies and racial and ethnic health 
disparities: a cautionary tale. Policy Polit Nurs Pract. 2010; 11(4):309–316. http://dx.doi.org/
10.1177/1527154411398490. [PubMed: 21531966] 
12. Wharam JF, Daniels N. Toward evidence-based policy making and standardized assessment of 
health policy reform. JAMA. 2007; 298(6):676–679. http://dx.doi.org/10.1001/jama.298.6.676. 
[PubMed: 17684191] 
13. Majumdar SR, Soumerai SB. The unhealthy state of health policy research. Health Aff (Millwood). 
2009; 28(5):w900–w908. http://dx.doi.org/10.1377/hlthaff.28.5.w900. [PubMed: 19671571] 
14. Shadish WR, Cook TD. The renaissance of field experimentation in evaluating interventions. Annu 
Rev Psychol. 2009; 60:607–629. http://dx.doi.org/10.1146/annurev.psych.60.110707.163544. 
[PubMed: 18616391] 
15. West SG, Duan N, Pequegnat W, et al. Alternatives to the randomized controlled trial. Am J Public 
Health. 2008; 98(8):1359–1366. http://dx.doi.org/10.2105/AJPH.2007.124446. [PubMed: 
18556609] 
16. Craig P, Cooper C, Gunnell D, et al. Using natural experiments to evaluate population health 
interventions: new Medical Research Council guidance. J Epidemiol Community Health. 2012; 
66(12):1182–1186. http://dx.doi.org/10.1136/jech-2011-200375. [PubMed: 22577181] 
17. Shadish, WR.; Cook, TD.; Campbell, DT. Experimental and quasi-experimental designs for 
generalized causal inference. Houghton Mifflin; Boston: 2001. p. xxip. 623
18. Durlauf, SN.; Blume, L. The New Palgrave Dictionary of Economics. 2nd ed. Palgrave Macmillan; 
New York: 2008. 
19. Petticrew M, Cummins S, Ferrell C, et al. Natural experiments: an underused tool for public 
health? Public Health. 2005; 119(9):751–757. http://dx.doi.org/10.1016/j.puhe.2004.11.008. 
[PubMed: 15913681] 
20. Callinan JE, Clarke A, Doherty K, Kelleher C. Legislative smoking bans for reducing secondhand 
smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev. 
2010; (4):CD005992. [PubMed: 20393945] 
21. Costello EJ, Compton SN, Keeler G, Angold A. Relationships between poverty and 
psychopathology: a natural experiment. JAMA. 2003; 290(15):2023–2029. http://dx.doi.org/
10.1001/jama.290.15.2023. [PubMed: 14559956] 
22. Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial infarction 
associated with public smoking ban: before and after study. BMJ. 2004; 328(7446):977–980. 
http://dx.doi.org/ 10.1136/bmj.38055.715683.55. [PubMed: 15066887] 
23. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs 
under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987; 317(9):550–556. http://
dx.doi.org/10.1056/NEJM198708273170906. [PubMed: 3302713] 
24. Baicker K, Taubman SL, Allen HL, et al. The Oregon experiment—effects of Medicaid on clinical 
outcomes. N Engl J Med. 2013; 368(18):1713–1722. http://dx.doi.org/10.1056/NEJMsa1212321. 
[PubMed: 23635051] 
Ackermann et al. Page 9













25. Ludwig J, Sanbonmatsu L, Gennetian L, et al. Neighborhoods, obesity, and diabetes—a 
randomized social experiment. N Engl J Med. 2011; 365(16):1509–1519. http://dx.doi.org/
10.1056/NEJMsa1103216. [PubMed: 22010917] 
26. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res 
Methodol. 2006; 6:54. http://dx.doi.org/10.1186/ 1471-2288-6-54. [PubMed: 17092344] 
27. Donner, A.; Klar, N. Design and Analysis of Cluster Randomization Trials in Health Research. 
Arnold; Co-published by the Oxford University Press; New York, NY: 2000. p. xp. 178
28. Schmittdiel JA, Grumbach K, Selby JV. System-based participatory research in health care: an 
approach for sustainable translational research and quality improvement. Ann Fam Med. 2010; 
8(3):256–259. http://dx.doi.org/10.1370/afm.1117. [PubMed: 20458110] 
29. Stokols D. Translating social ecological theory into guidelines for community health promotion. 
Am J Health Promot. 1996; 10(4):282–298. http://dx.doi.org/10.4278/0890-1171-10.4.282. 
[PubMed: 10159709] 
30. Whittemore R, Melkus GD, Grey M. Applying the social ecological theory to type 2 diabetes 
prevention and management. J Community Health Nurs. 2004; 21(2):87–99. http://dx.doi.org/
10.1207/s15327655jchn2102_03. [PubMed: 15123438] 
31. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic 
illness: the chronic care model, Part 2. JAMA. 2002; 288(15):1909–1914. http://dx.doi.org/
10.1001/jama.288.15.1909. [PubMed: 12377092] 
32. Mangione CM, Gerzoff RB, Williamson DF, et al. The association between quality of care and the 
intensity of diabetes disease management programs. Ann Intern Med. 2006; 145(2):107–116. 
http://dx.doi.org/10.7326/0003-4819-145-2-200607180-00008. [PubMed: 16847293] 
33. Agency for Healthcare Research and Quality. Designing and Implementing Medicaid Disease and 
Care Management Programs: A User's Guide. Rockville, MD: Mar. 2008 2008. Report No.: 
AHRQ Publication No. 07(08)-0063
34. Brown R, Peikes D, Chen A, Schore J. 15-site randomized trial of coordinated care in Medicare 
FFS. Health Care Financ Rev. 2008; 30(1):5–25.
35. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 
2007; 26(2):w195–w203. http://dx.doi.org/10.1377/hlthaff.26.2.w195. [PubMed: 17264100] 
36. Spaulding A, Fendrick AM, Herman WH, et al. A controlled trial of value-based insurance design
—The MHealthy: Focus on Diabetes (FOD) trial. Implement Sci. 2009; 4:19. http://dx.doi.org/
10.1186/1748-5908-4-19. [PubMed: 19351413] 
37. Newlin K, Dyess SM, Allard E, Chase S, Gail D'Eramo M. A methodological review of faith-based 
health promotion literature: advancing the science to expand delivery of diabetes education to 
black Americans. J Relig Health. 2011; 51(4):1075–1097. http://dx.doi.org/10.1007/
s10943-011-9481-9. 
38. Schmittdiel JA, Brown SD, Neugebauer R, et al. Health-plan and employer-based wellness 
programs to reduce diabetes risk: The Kaiser Permanente Northern California NEXT-D Study. 
Prev Chronic Dis. 2013; 10:E15. http://dx.doi.org/10.5888/pcd10.120146. [PubMed: 23369768] 
39. Duru OK, Mangione CM, Chan C, et al. Evaluation of the diabetes health plan to improve diabetes 
care and prevention. Prev Chronic Dis. 2013; 10:E16. http://dx.doi.org/10.5888/pcd10.120150. 
[PubMed: 23369769] 
40. Albu J, Sohler N, Matti-Orozco B, et al. Expansion of electronic health record-based screening, 
prevention, and management of diabetes in New York City. Prev Chronic Dis. 2013; 10:E13. http://
dx.doi.org/10.5888/pcd10.120148. [PubMed: 23369766] 
41. Kaiser Family Foundation. Employer health benefits 2013 annual survey. The Kaiser Family 
Foundation and Health Research & Educational Trust; Menlo Park, CA: 2013. http://ehbs.kff.org/
42. Haviland AM, Marquis MS, McDevitt RD, Sood N. Growth of consumer-directed health plans to 
one-half of all employer-sponsored insurance could save $57 billion annually. Health Aff 
(Millwood). 2012; 31(5):1009–1015. http://dx.doi.org/10.1377/hlthaff.2011.0369. [PubMed: 
22566440] 
43. Wharam JF, Galbraith AA, Kleinman KP, Soumerai SB, Ross-Degnan D, Landon BE. Cancer 
screening before and after switching to a high-deductible health plan. Ann Intern Med. 2008; 
Ackermann et al. Page 10













148(9):647–655. http://dx.doi.org/10.7326/0003-4819-148-9-200805060-00004. [PubMed: 
18458277] 
44. Wharam JF, Landon BE, Galbraith AA, Kleinman KP, Soumerai SB, Ross-Degnan D. Emergency 
department use and subsequent hospitalizations among members of a high-deductible health plan. 
JAMA. 2007; 297(10):1093–1102. http://dx.doi.org/10.1001/jama.297.10.1093. [PubMed: 
17356030] 
45. Wharam JF, Soumerai S, Trinacty C, et al. Impact of emerging health insurance arrangements on 
diabetes outcomes and disparities: rationale and study design. Prev Chronic Dis. 2013; 10:E11. 
http://dx.doi.org/10.5888/pcd10.120147. [PubMed: 23369764] 
46. Ackermann RT, Holmes AM, Saha C. Designing a natural experiment to evaluate a national health 
care-community partnership to prevent type 2 diabetes. Prev Chronic Dis. 2013; 10:E12. http://
dx.doi.org/10.5888/pcd10.120149. [PubMed: 23369765] 
Ackermann et al. Page 11














Relationships of NEXT-D Research Projects across the Landscape of Stakeholders that 
Influence Diabetes Prevention and Control.
Note: The framework shown is an adaptation of socio-ecological models, depicting the 
spectrum, levels, and reach of different health system, societal, industry, and governmental 
stakeholder policies that may influence diabetes incidence, progression, and outcomes. The 
dashed lines separating stakeholders convey bidirectional and fluid interactions across levels. 
Numbered indicators represent the positioning of different NEXT-D studies, specifically:
1. Kaiser Permanente Northern California evaluation of health plan 
detection, outreach, and incentives for preventive care.
2. University of California Los Angeles evaluation of a disease specific 
health plan for patients with prediabetes or diabetes offered by employers 
to reduce costs of care.
3. New York St. Luke's Roosevelt Hospital Center evaluation of the use of an 
electronic medical record system for diabetes risk detection and prevention 
in community health centers and other outpatient clinics.
4. Harvard University evaluation of the effects on diabetes outcomes of 
employer-mandated switching to a high deductible health plan.
5. Northwestern University evaluation of the reach, adoption, 
implementation, effectiveness, and costs of a commercial health payer 
policy to support diabetes prevention programs delivered in communities.
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Table 1
Hierarchy of Natural Experimental Study Designs and their Capacity to Address Threats to Internal Validity
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